Translational Cancer Medicine

Register for this event and receive complimentary access to: Biomarker Assay Development

Top 10 Opportunities in Translational Cancer Medicine:

1. Combination Therapies
2. New Targets
3. Molecular Diagnostics
4. Companion Diagnostics
5. Better in vitro Models
6. Better in vivo Models
7. Biomarkers to Predict Drug Response
8. Cancer Biologics
9. Phase 0 Clinical Trials
10. Translational Imaging

Additional Coverage:

• Case Studies in Oncology Drug Development
• Cancer Biomarkers
• Translation from In-House Development to Clinical Laboratory
• Circulating Tumor Cell Assays

PRE-CONFERENCE SHORT COURSES:

• Novel Cancer Biomarkers
• Fit-for-Purpose Biomarker Assay Development and Validation

Featured Speakers:

Jon M. Wigginton,
Director, Clinical Oncology,
Merck

Francis Kalush,
Network Leader, Diagnostics,
CDRH, FDA

Scott D. Patterson,
Executive Director, Medical Sciences,
Amgen

James Christensen,
Director, Translational Pharmacology
Pfizer

Anne-Marie Martin,
Director, Oncology,
GlaxoSmithKline

Herbert A. Fritsche,
Chief, Clinical Chemistry,
M.D. Anderson Cancer Center

J. Milburn Jessup,
Chief, Diagnostics Evaluation Branch,
DCTD, NCI

Martin Fleisher,
Chair, Clinical Laboratories,
Memorial Sloan-Kettering
Cancer Center